. Author manuscript; available in PMC: 2014 Dec 10.

Published in final edited form as: Cochrane Database Syst Rev. 2013 Feb 28;2:CD006539. doi: 10.1002/14651858.CD006539.pub3

Table 3.

Characteristics of studies awaiting assessment [ordered by study ID]

NCT00141882
Methods	Randomized, double-blind, placebo-controlled, parallel assignment study (phase III trial) Enrollment: 1100 participants.
Participants	Adults (18 to 80 years) with open angle glaucoma. Inclusion criteria: glaucoma damage on examination of the visual field and optic disc; good visual acuity (with glasses if needed)
Interventions	3 arms: high-dose memantine; low-dose memantine; and placebo
Outcomes	Primary outcome: progression of glaucoma.
Notes	Study sponsored by Allergan, Inc. Study was completed as of 18 December 2007. Study information collected from trial registration and press release by Allergan, Inc
NCT00168350
Methods	Randomized, double-blind, placebo-controlled, parallel assignment study (phase III trial) Enrollment: 1100 participants.
Participants	Adults (18–80 years) with open angle glaucoma. Inclusion criteria: glaucoma damage on examination of the visual field and optic disc; good visual acuity (with glasses if needed)
Interventions	3 arms: high-dose memantine; low-dose memantine; and placebo
Outcomes	Primary outcome: progression of glaucoma.
Notes	Study sponsored by Allergan, Inc. Study was completed as of 18 December 2007. Study information collected from trial registration and press release by Allergan, Inc

It is not clear which trial numbers correspond to the first study completed and the second study completed. Press release only mentions that the results of the second phase III trial differed from the first phase III trial.